SG11201506640TA - Anti-stress agent - Google Patents

Anti-stress agent

Info

Publication number
SG11201506640TA
SG11201506640TA SG11201506640TA SG11201506640TA SG11201506640TA SG 11201506640T A SG11201506640T A SG 11201506640TA SG 11201506640T A SG11201506640T A SG 11201506640TA SG 11201506640T A SG11201506640T A SG 11201506640TA SG 11201506640T A SG11201506640T A SG 11201506640TA
Authority
SG
Singapore
Prior art keywords
stress agent
stress
agent
Prior art date
Application number
SG11201506640TA
Inventor
Toshihiro Sashihara
Masashi Nagata
Takeshi Mori
Original Assignee
Meiji Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Co Ltd filed Critical Meiji Co Ltd
Publication of SG11201506640TA publication Critical patent/SG11201506640TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201506640TA 2013-02-27 2014-02-26 Anti-stress agent SG11201506640TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013037983 2013-02-27
PCT/JP2014/054629 WO2014132982A1 (en) 2013-02-27 2014-02-26 Anti-stress agent

Publications (1)

Publication Number Publication Date
SG11201506640TA true SG11201506640TA (en) 2015-09-29

Family

ID=51428245

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506640TA SG11201506640TA (en) 2013-02-27 2014-02-26 Anti-stress agent

Country Status (5)

Country Link
JP (1) JP6329125B2 (en)
CN (1) CN105025909B (en)
HK (1) HK1215854A1 (en)
SG (1) SG11201506640TA (en)
WO (1) WO2014132982A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017131402A1 (en) * 2016-01-28 2017-08-03 경희대학교 산학협력단 Novel human gut-derived lactic acid bacteria having immune regulatory function, and use thereof
WO2017183595A1 (en) * 2016-04-20 2017-10-26 株式会社 明治 Fermented milk for ameliorating feeling of fatigue
WO2018003900A1 (en) * 2016-06-30 2018-01-04 アサヒグループホールディングス株式会社 Composition for use in improvement of nutritional state
WO2018021435A1 (en) * 2016-07-27 2018-02-01 株式会社マイトス Composition including hydrogen as active ingredient, for improving exercise endurance or for alleviating fatigue perceived after exercise
KR20180019474A (en) * 2016-08-16 2018-02-26 주식회사 엠디헬스케어 Composition for Prevention or Treatment of Mental Disorders Comprising Extracellular Vesicles Derived from Lactic acid bacteria
CA3036197C (en) * 2016-09-09 2023-02-28 Kirin Kabushiki Kaisha Composition comprising lactobacillus paracasei for suppressing or improving eye fatigue
JP6815139B2 (en) * 2016-09-09 2021-01-20 キリンホールディングス株式会社 Composition for suppressing age-related retinal cell death containing lactic acid bacteria as an active ingredient
WO2018073963A1 (en) * 2016-10-21 2018-04-26 森永乳業株式会社 Profile of mood state improving agent
JP7134703B2 (en) * 2018-05-16 2022-09-12 株式会社明治 Adrenal hypofunction inhibitor
JP7433220B2 (en) * 2018-06-04 2024-02-19 株式会社明治 Composition for the treatment of paramenstrual symptoms
JP2020039308A (en) * 2018-09-12 2020-03-19 キリンホールディングス株式会社 Composition for improving labor performance
JP7224586B2 (en) * 2019-01-10 2023-02-20 日本メナード化粧品株式会社 Immunity evaluation method
JP7369992B2 (en) * 2019-05-13 2023-10-27 株式会社明治 Fermented milk for improving autonomic nervous function
AU2020289102A1 (en) * 2019-06-03 2022-01-20 Asahi Group Holdings, Ltd. Walking ability improver
CA3151435A1 (en) * 2019-11-05 2021-05-14 Claes THULIN 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4<i>h</i>-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal
US20230000933A1 (en) * 2019-12-02 2023-01-05 Life Quality Institute, Inc. Agent for prevention or remediation of stress disorders and composition containing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2793257B1 (en) * 1999-05-06 2001-07-27 Gervais Danone Sa LACTIC BACTERIA WITH ANXIOLYTIC PROPERTIES, AND USES THEREOF
JP4853986B2 (en) * 2001-09-20 2012-01-11 雪印メグミルク株式会社 Preventive and therapeutic agent for inflammatory bowel disease and irritable bowel syndrome
JP5394628B2 (en) * 2007-02-09 2014-01-22 クロスフィールドバイオ株式会社 Novel Lactobacillus microorganisms and lactic acid bacteria preparations
JP2013047192A (en) * 2011-08-29 2013-03-07 Meiji Co Ltd Lactobacillus promoting physical activity
CN102726524B (en) * 2012-06-19 2014-05-28 重庆市天友乳业股份有限公司 Probiotics fermentation milk

Also Published As

Publication number Publication date
WO2014132982A1 (en) 2014-09-04
HK1215854A1 (en) 2016-09-23
JPWO2014132982A1 (en) 2017-02-02
JP6329125B2 (en) 2018-05-23
CN105025909A (en) 2015-11-04
CN105025909B (en) 2020-05-19

Similar Documents

Publication Publication Date Title
DK3689865T3 (en) Hidtil ukendte aminopyrimidinderivater
DK3088517T3 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
HK1215854A1 (en) Anti-stress agent
DK3736291T3 (en) Anti-FCRH5-antistoffer
DK3354246T3 (en) Udstyrsmonteringssystem
DK3077519T3 (en) Cmv-vacciner
EP3000028A4 (en) Auto-calendaring
EP2960327A4 (en) Immunostimulation agent
GB201317658D0 (en) isizeme
DK3470074T3 (en) Probiotika
AU353644S (en) Stamphousing
DK3056208T3 (en) Immunpotentiator
IL245464A0 (en) Spiro-oxazolones
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
EP3037100A4 (en) Muscle-atrophy-preventing agent
EP3014557A4 (en) Phone-on-file
DK2989854T3 (en) Strømstyret opvarmningssystem
AU4899P (en) Herbie53 Iresine herbstii
AU4953P (en) Flogazora Gazania rigens
AU4977P (en) Harrosy Gaura lindheimeri
AU353328S (en) Kettlebell
AU353327S (en) Kettlebell
AU353329S (en) Kettlebell
AU353326S (en) Kettlebell
AU353331S (en) Kettlebell